“...pleasure and pain, they come and go and don't last... bear them patiently”
—Gita
Pathos InvestmentsEquity Research
Research  ›  Fact Sheets  ›  AMGN

AMGEN INC

LISTEDNASDAQ
SYMBOLAMGN
SIC2836
STATE OF INC.DE
FISCAL YEAR ENDSDecember 31
CIK318154

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

REVENUES, NET INCOME AND FREE CASH FLOW BY FISCAL YEAR$ billions0102030402016201720182019202020212022202320242025RevenuesNet incomeFree cash flowEARNINGS AND DIVIDENDS PER SHARE$ per share0.005.0010.0015.002016201720182019202020212022202320242025EPS dilutedDividends per share

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)Amount%
Total debt54,60486.3
Stockholders' equity8,65813.7
Total capitalization63,262100.0

540,632,005 shares outstanding at 30 July 2026 (cover page of the 10-Q filed 5 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)Amount
Long-term debt, incl. current maturities54,604
Long-term debt, noncurrent50,005
Current maturities4,599
Short-term borrowings / commercial paper0

CAPITAL STOCK 12/31/25

Common shares authorized2,750,000,000
Par or stated value per share ($)0.0001
Outstanding at 7/30/26540,632,005

DIVIDENDS DECLARED/PAID

Fiscal yearPer share $Payout %
20259.6667.9
20249.13120.8
20238.6469.2
20227.9565.6
20217.2270.2

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2836, Biological Products, (No Diagnostic Substances). Large accelerated filer. Principal executive office: One Amgen Center Drive, Thousand Oaks, CA 91320. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)12/31/2512/31/2412/31/23
Revenues36,75133,42428,190
Cost of revenues12,03712,8588,451
Research and development7,2725,9644,784
Selling, general and administrative7,0507,0966,179
Depreciation and amortization5,1675,5924,071
Operating income9,0807,2587,897
Interest expense2,7553,1552,875
Income before income taxes8,9764,6097,855
Income taxes1,2655191,138
Net income7,7114,0906,717
Earned per share, diluted ($)14.237.5612.49
Dividends per share ($)9.669.138.64

CONSOLIDATED BALANCE SHEET

($ millions)12/31/2512/31/24
Cash and equivalents9,12911,973
Receivables, net9,5706,782
Inventories6,2256,998
Total current assets29,05729,030
Property, plant and equipment, net7,9136,543
Goodwill18,68018,637
Total assets90,58691,839
Total current liabilities25,48923,099
Long-term debt50,00556,549
Stockholders' equity8,6585,877
Total liabilities and equity90,58691,839

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year endedRevenuesOper. incomeNet incomeNet margin %EPS diluted $Div. per share $Oper. cash flowCapital expend.Free cash flowTotal assetsTotal liabilitiesTotal debtStockholders' equityROE %Debt / equity
12/31/2536,7519,0807,71121.014.239.669,9581,8588,10090,58681,928d54,6048,65889.16.31
12/31/2433,4247,2584,09012.27.569.1311,4901,09610,39491,83985,962d60,0995,87769.610.23
12/31/2328,1907,8976,71723.812.498.648,4711,1127,35997,15490,922d64,6136,232107.810.37
12/31/2226,3239,5666,55224.912.117.959,7219368,78565,12161,460d38,9453,661179.010.64
12/31/2125,9797,6395,89322.710.287.229,2618808,38161,16554,465d33,3096,70088.04.97
12/31/2025,4249,1397,26428.612.316.5610,4976089,88962,94853,539d32,9869,40977.23.51
12/31/1923,3629,6747,84233.612.885.959,1506188,53259,70750,034d29,9039,67381.13.09
12/31/1823,74710,2638,39435.312.625.4111,29673810,55866,41653,916d33,92912,50067.22.71
12/31/1722,8499,9731,9798.72.694.7711,17766410,51379,95454,713d35,34225,2417.81.40
12/31/1622,9919,7947,72233.610.244.1510,3547389,61677,62647,751d34,59629,87525.81.16

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

AMGEN INC
CIK 318154 · EIN 95-3540776

PRINCIPAL OFFICE:

One Amgen Center Drive, Thousand Oaks, CA 91320
Tel.: (805)447-1000

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2836 · Biological Products, (No Diagnostic Substances)

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 13 February 2026

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

8/5/2610-Qperiod 6/30/26
8/4/268-Kperiod 8/4/26
7/31/268-Kperiod 7/29/26
5/20/268-Kperiod 5/19/26
5/19/268-Kperiod 5/19/26
5/1/2610-Qperiod 3/31/26
4/30/268-Kperiod 4/30/26
4/22/268-Kperiod 4/22/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/13/26) · 10-K FY2024 (filed 2/14/25) · 10-K FY2023 (filed 2/14/24) · 10-K FY2022 (filed 2/9/23) · 10-K FY2021 (filed 2/16/22) · 10-K FY2020 (filed 2/9/21) · 10-K FY2019 (filed 2/12/20) · 10-K FY2018 (filed 2/13/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.

Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.

Data from SEC filings  ·  Educational only  ·  Not investment advice